Upifitamab (Anti-SLC34A2) is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize an ADC compound, Upifitamab rilsodotin, used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. MW : 145.5 KD.